<DOC>
	<DOCNO>NCT01501487</DOCNO>
	<brief_summary>Genomics assay measure specific gene expression pattern patient 's primary tumor become important prognostic tool breast cancer patient . This study design test ability MammaPrint® combination TargetPrint® , BluePrint® , TheraPrint® , well traditional pathologic clinical prognostic factor , predict responsiveness neo-adjuvant chemotherapy patient locally advance breast cancer ( LABC ) .</brief_summary>
	<brief_title>MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I</brief_title>
	<detailed_description>Patients suspect primary breast cancer mammography clinical examination assess eligibility needle core biopsy confirm invasive carcinoma . A fresh unfixed tumor specimen , incisional core biopsy send Agendia determine MammaPrint risk profile , BluePrint molecular subtyping profile , TargetPrint ER , PR HER2 single gene readout , 56-geneTheraPrint Research Gene Panel additional gene measure whole genome ( 44k ) array . Surgical Protocol : 1 . Determination nodal status : - For clinically node-negative patient : Axillary ultra sound , follow Sentinel Lymph Node ( SLN ) biopsy - For clinically node-positive patient : ultra sound-guided Fine Needle Aspirate ( FNA ) , follow core biopsy 2 . Neo-adjuvant chemotherapy 3 . Definitive surgery : - For node-positive patient : lumpectomy , repeat SLN biopsy , Axillary Lymph Node Dissection ( ALND ) - For node-negative patient : lumpectomy , repeat SLN biopsy ( optional ) , ALND Response measure pathological Complete Response ( pCR ) centrally assess Residual Cancer Burden ( RCB ) .</detailed_description>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Pertuzumab</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Women histologically proven invasive breast cancer distant metastasis ; Lymphnode negative clinical tumor classification T2 ( ≥3.5cm ) T4 13 positive lymph node clinical tumor classification T2T4 DCIS LCIS allow addition invasive cancer T2 T3 level . Age ≥ 18 year . At least one lesion accurately measure two dimension utilize mammogram , ultrasound , MRI image define specific size validate complete pathologic response . Adequate bone marrow reserve ( neutrophil count &gt; 1.5 x109 /l platelet count &gt; 100 x109/l ) , adequate renal function ( serum creatinine ≤ 1.5 x upper limit normal ) hepatic function ( ALAT , ASAT ≤ 2.5 x upper limit normal , alkaline phosphatase ≤ 2.5 x upper limit normal total bilirubin ≤ 2.0 x upper limit normal ) . Signed informed consent patient Any patient confirm metastatic disease . Patients inflammatory breast cancer . Tumor sample ship Agendia ≤ 30 % tumor cell fail Quality Assurance Quality Control criterion . Patients prior chemotherapy , radiotherapy , endocrine therapy treatment breast cancer . Any serious uncontrolled intercurrent infection , serious uncontrolled concomitant disease .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>neo adjuvant therapy</keyword>
</DOC>